Table 2.
Two-year Inverse Probability of Censoring-Weighted Effect Estimates of Acute Gastroenteritis-related Emergency Department Visits by Protocol, United States, 2009-2016a,b
| Protocol | No. of events |
No. of person– years at risk |
Risk,% (95% CI) b |
Risk Difference, % (95% CI) b |
Vaccine Effectiveness (%) (95% CI) c |
|
|---|---|---|---|---|---|---|
| P1 | Unvaccinated series | 2,416 | 99,818 | 4.36 (4.17, 4.57) | 0.00 | |
| P2 | Partial RV5 series (1 dose) | 2,695 | 161,729 | 4.57 (4.04, 5.16) | 0.20 (−0.38, 0.79) | −5 (−18, 9) |
| P3 | Partial RV5 series (2 doses) | 5,585 | 321,969 | 4.23 (3.95, 4.54) | −0.13 (−0.49, 0.23) | 3 (−5, 11) |
| P4 | Full RV5 series (3 doses) | 15,297 | 885,993 | 3.15 (3.09, 3.21) | −1.22 (−1.43, −1.00) | 28 (24, 32) |
| P5 | Partial RV1 series (1 dose) | 699 | 38,563 | 4.07 (3.42, 4.84) | −0.30 (−1.03, 0.43) | 7 (−10, 23) |
| P6 | Full RV1 series (2 doses) | 3,235 | 184,002 | 3.15 (3.04, 3.27) | −1.21 (−1.43, −0.99) | 28 (24, 32) |
a
Estimates adjusted for month of birth, year of birth, gender, maternal age, number of siblings, overnight hospitalization, health plan type, network of provider type, residence in a metropolitan statistical area, and geographic region.
b
95% confidence intervals estimated using a non-parametric bootstrap (N=200).
c
Vaccine effectiveness calculated as (1 – risk ratio) x 100.
CI indicates confidence interval; RV1, rotavirus monovalent vaccine; RV5, rotavirus pentavalent vaccine.